117 results about "ARDS" patented technology

The invention relates to the technical field of biomedical engineering, and discloses an acute respiratory distress syndrome mechanical ventilation adaptive adjustment control system, which comprises a data acquisition module, a signal preprocessing module, a physiological parameter calculation module, a prediction module, a decision and control logic module and the like. Wherein the prediction module predicts a dynamic lung compliance change trend by using a long short-term memory neural network model, and the decision and control logic module generates a ventilation parameter adjustment instruction according to a prediction result and a clinical safety rule. By adopting the technical scheme, the system overcomes the hysteresis of traditional feedback regulation, reduces the risk of breathing machine related lung injury, optimizes oxygenation and carbon dioxide removal efficiency, and provides an accurate, safe and individualized mechanical ventilation treatment scheme.

The invention discloses a prone position ARDS patient death risk prediction system based on interpretable machine learning, which constructs an interpretable machine learning prediction model based on clinical data of an ARDS patient before the ARDS patient receives prone position ventilation treatment, and is used for identifying high-death-risk crowds in an ICU (Intensive Care Unit). According to the method, an optimal prediction model is determined by performing preprocessing and correlation and collinearity screening on original variables, selecting key features by adopting Lasso regression and combining multi-model training and cross validation. On the basis, an SHAP method is introduced to explain a model decision basis, a column graph is constructed, visual expression of a risk assessment result is realized, and clinical understandability and practicability of the model are improved, so that auxiliary support is provided for precise treatment and resource allocation.

The invention relates to the technical field of bioinformatics, in particular to a method for typing acute respiratory distress syndrome biological subtypes. The method comprises the following steps: a) acquiring multi-omics data and carrying out standardized preprocessing; the multi-omics data comprises transcriptomics data, proteomics data and metabonomics data of a biological sample source; b) constructing a similarity network of each group by using a similarity fusion network (SNF), and obtaining a uniform sample similarity matrix through multi-group network fusion and iteration; multiple collaborative principal component analysis (MCIA) is adopted to carry out dimension reduction on multi-omics data so as to realize visualization of a clustering result; carrying out multi-omics joint discrimination modeling under the guidance of SNF clustering by using a data integration analysis (DIABLO) method so as to identify key feature variables; and carrying out biological subtype classification based on the clustering result of the steps.

The invention belongs to the technical field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition for treating acute respiratory distress syndrome and a preparation and a preparation method thereof, and the traditional Chinese medicine composition is prepared from the following raw materials: 12-30g of ginseng, 6-30 parts of rheum officinale, 9-30 parts of salvia miltiorrhiza and 3-15 parts of semen lepidii. Pharmacological experiments prove that the traditional Chinese medicine composition can improve lung inflammation infiltration to different degrees, improve lung tissue structure disorder and relieve pulmonary edema, and the clinical death rate is remarkably reduced in clinical application; the prepared preparation, especially granules, can be stored for 36 months for a long time, and is suitable for further industrial mass production.

The invention relates to application of bifidobacterium animalis in preparation of a product for preventing, treating or adjunctively treating pneumonia, and belongs to the technical field of microorganisms. The invention aims to solve the technical problem that the existing treatment of acute lung injury (ALI) / acute respiratory distress syndrome (ARDS) is mainly based on supportive means and lacks special-effect treatment drugs. According to the key point of the technical scheme, a new strain, namely the Bifidobacterium animalis ORG01 is provided, the preservation number is GDMCC NO: 67122, and the strain has good technical effects in the aspects of improving the acute lung injury effect, the strain stability, the product application convenience and the like. According to an experimental test, the bifidobacterium animalis ORG01 disclosed by the invention can be used for remarkably recovering the lung organ index of an LPS-induced acute lung injury model mouse, the TNF-alpha content in serum and the mRNA expression level of IL-6 in lung tissues to normal levels.

The present invention relates to the early treatment, including pre-diagnosis treatment, of sepsis and acute inflammatory syndromes such as systemic inflammatory response syndrome (SIRS) by PLA2 and metalloprotease inhibitors to improve the performance of antibiotics and outcomes prior to and after confirmation of the diagnosis of sepsis and / or SIRS in a patient or subject. Additional embodiments include methods of treating sepsis, anthrax and severe acute respiratory syndrome coronavirus (SARS and SARS-CoV2) and related inflammatory syndromes and compositions, including pharmaceutical compositions and blood sample compositions. In further embodiments, the present invention is directed to embodiments which evidence that LY315920, LY333013 and related sPLA2 inhibitors are particularly effective COVID-19 / cytokine release syndrome therapeutics-prophylactics. In embodiments, the PLA2 inhibitor is varespladib (LY315920), methyl varespladib (LY333013), AZD2716-(R)-3-(5′-benzyl-2′-carbamoyl-[1,1′-biphenyl]-3-yl)-2-methylpropanoic acid—as a racemic mixture or separately, as the “R” enantiomer), compound 4 (3-(5′-benzyl-2′-carbamoyl-[1,1′-biphenyl]-3-yl)-propanoic acid) and LY433771 ((9-[(phenyl)methyl]-5-carbamoylcarbazol-4-yl) oxyacetic acid), a pharmaceutically acceptable salt thereof or a mixture thereof. In embodiments, the metalloprotease inhibitor is Prinomastat, Batimastat, marimastat or vorinostat dosed alone or in combination with preferred sPLA2 inhibitors for the treatment of infection, inflammatory and wound conditions arising from various causes. Methods and compositions for achieving accelerated treatment of wounds and burns, anthrax metalloprotease toxin (lethal factor) driven complications, ARDS, neo-natal and pediatric acute respiratory distress syndrome (neo-natal / pediatric ARDS), including meconium aspiration syndrome and other disease states and conditions are also disclosed.

The present invention relates to the field of medicines and relates to a fused five-membered and six-membered heterocyclic compound, a preparation method therefor, and a use thereof in the field of pharmaceuticals. Specifically, the present invention provides a compound having a structure represented by formula (I), or a stereoisomer, a tautomer, a solvate, a metabolite, a pharmaceutically acceptable salt, or a prodrug thereof. The compound and a pharmaceutical composition thereof of the present invention can be used for preparing a medicament for treating HIF-2α-mediated related diseases, such as renal anemia, chronic kidney disease, chronic metabolic disease, neurodegenerative disease, infection, inflammatory disease, pulmonary edema, and acute respiratory distress syndrome.

The application relates to kaempferol cerium nanoparticles and a preparation method and application thereof, and belongs to the technical field of biological medicines. The kaempferol cerium nanoparticles are prepared by performing coordination co-assembly on kaempferol and cerium ions in the presence of polyethylene glycol at a specific molar ratio, and the nanoparticles have uniform particle sizes and good dispersity. The nanoparticles have the anti-inflammatory activity of kaempferol and the ROS scavenging capacity of cerium ions, and show a significant synergistic effect in in-vivo and in-vitro experiments, can effectively reduce lung inflammation, inhibit oxidative stress, improve lung function, and have good biological safety, thereby providing a new drug candidate scheme for the treatment of ARDS.

Disclosed herein is a method for treating, preventing, and / or slowing the progression of various chronic inflammatory condition groups including: (1) the Type 2 Diabetes group (Metabolic Syndrome (MET), obesity, hyperglycemia); (2) ARDS (Acute Respiratory Distress Syndrome); (3) chronic autoimmune inflammatory conditions (Rheumatoid Arthritis (RA), Lupus, and Psoriasis); (4) inflammatory bowel diseases (IBD), such as Crohn's disease and ulcerative colitis; (5) metabolite group-mediated diseases (atherosclerosis, hypertension, and congestive heart failure); and (6) eating disorders, such as Prader-Willi Syndrome and other monogenic and symptomatic obesity disorders including leptin pathway defects, each method comprising orally administering a pharmaceutical composition comprising a denatonium salt. The present disclosure is based on the results of a series of studies that tracked biomarker cluster levels to track mediators of inflammatory conditions and mediators of gut signaling hormones in response to orally administered denatonium salts.

The present disclosure relates to the detection of acute respiratory distress syndrome in a patient. Subjects of the present disclosure are a computer system, a method and a computer program product for detection of acute respiratory distress syndrome.

The application relates to the field of biological medicine, discloses application of a biomarker in an in-vitro auxiliary diagnosis product of sepsis complicated with ARDS, the biomarker is PDLIM1 in peripheral blood; further includes a detection kit and a use method thereof. The application first proposes that the PDLIM1 protein can be used as a biomarker to detect sepsis complicated with ARDS, compared with detection by means of a "combined judgment" method, the detection product can help medical staff to perform rapid detection, and in a ROC curve diagram, the AUC of PDLIM1 is greater than 0.8, the detection result is reliable, and the operation mode is relatively simple, so that the detection time is compressed, and the medical starting time is reduced.

The invention belongs to the technical field of biological medicine, and relates to application of miRNA targeted regulation in treatment of acute respiratory distress syndrome, in particular to application of a miR-144 inhibitor in preparation of a medicine for improving glucocorticoid treatment sensitivity of an ARDS patient. Research on a lipopolysaccharide-induced ARDS rat model finds that miR-144 participates in regulation and control of glucocorticoid receptor beta (GR beta) and NF-kappa B signal pathways in the ARDS inflammatory reaction process, the number of neutrophils in alveolar lavage fluid and the level of inflammatory factors such as IL-6 and TNF-alpha can be remarkably reduced by using the miR-144 inhibitor and glucocorticoid for treatment, and the application of the miR-144 inhibitor to treatment of the pulmonary alveolar lavage fluid in the treatment of the pulmonary alveolar lavage fluid is broad. The wet-to-dry ratio and pathological injury score of lung tissues are reduced, and GR beta and NF-kappa B expression is inhibited, so that the anti-inflammatory effect of glucocorticoid is remarkably enhanced. The invention provides a treatment strategy for improving glucocorticoid resistance of ARDS patients by taking miR-144 as a target for the first time, and provides a new drug target and a technical scheme for accurate treatment of ARDS.

The invention discloses a biomarker, a kit, a system, a method and application for acute respiratory syndrome (ARDS) inflammation phenotype typing. The biomarker combination is selected from any two or a combination of more than two of PLAUR, BSG, TNFRSF14, DFFA, IFNGR1, ENAH, LAIR1, NUB1, AGRN, LTBR, BTN3A2 and F2R, and the biomarker combination is a combination of any two or more of PLAUR, BSG, TNFRSF14, DFFA, IFNGR1, ENAH, LAIR1, NUB1, AGRN, LTBR, BTN3A2 and F2R. By detecting the expression level of the marker in serum of a subject and utilizing a machine learning classification model (such as XGBoost) for analysis, ARDS patients can be divided into three phenotypes of C1 (high inflammation and high injury), C2 (low inflammation repair) and C3 (intermediate). The typing method can accurately predict clinical outcomes such as the 90-day death rate of the patient and guide individualized application of glucocorticoid and PEEP ventilation strategies, and has important significance for achieving accurate treatment of ARDS.

Liposomal trans-crocetin pharmaceutical compositions, dosing regimens and methods of treating or preventing disorders and conditions associated with, but not limited to, infection, ischemia, hypoxia, ARDS, inflammation, sepsis, shock, stroke, traumatic injury, and proliferative disorders such as cancer are provided. Methods of using the provided trans-crocetin pharmaceutical compositions and dosing regimens to treat cardiovascular, renal, liver, inflammatory, metabolic, pulmonary, neurological, and other disorders and conditions are also provided, as are methods of increasing the delivery of oxygen and increasing the efficacy of a therapeutic agent using the provided compositions and dosing regimens.

The present invention relates to the use of antisecretory factor (AF) protein, homologues, and / or fragments thereof, having equivalent functional activity, and / or a pharmaceutically active salt thereof, for restoring and / or normalizing epithelial barrier function for treating and / or preventing acute respiratory failure.In particular, antisecretory factor (AF) protein, homologues, and / or fragments thereof, having equivalent functional activity, and / or a pharmaceutically active salt thereof, is (are) herein disclosed to be of use in counteracting and / or normalizing fluid transfer across epithelial cell barriers with a significant impact on a large proportion of patients with traumatic lung injury, such as but not limited to patients suffering from abnormal accumulation of fluid in the lung alveoli and / or bronchioles selected from the list of patients suffering from BPD, ARDS, IRDS, sepsis, SIRS, acute pulmonary edema, pneumonia, interstitial pulmonary edema and cardiovascular lung disorder.

The invention relates to the technical field of bioengineering, in particular to a targeting nanoparticle for treating acute respiratory distress syndrome as well as a preparation method and application of the targeting nanoparticle. Comprising the following steps: (1) combining MP peptide with DSPE-PEG2000-MAL through a maleimide-mercaptan reaction, dialyzing the obtained conjugate, washing, and freeze-drying, so as to obtain a DSPE-PEG2000-MP conjugate; and (2) mixing the conjugate, lipid, a pharmaceutical preparation and a solvent, removing the solvent to obtain a lipid film, hydrating the lipid film, and performing membrane extrusion to obtain the nanoparticles. The invention not only provides a novel efficient and safe ARDS treatment scheme, but also provides an innovative mode for the design of a nano-drug delivery system based on cell mediation. And due to the dual targeting capability, excellent anti-inflammatory efficiency and good biocompatibility, the nano-material has a wide prospect in clinical application.

The application discloses a lung inflammation lesion quantitative evaluation artificial intelligence model based on CT images and relates to the field of artificial intelligence models.The model comprises CT image preprocessing, self-supervised lesion segmentation and quantification, multi-modal joint pre-training coding and multi-task diagnosis and prognosis prediction module composition which are sequentially and communicatively connected, and realizes feature interaction through a unified feature embedding space.The model realizes self-supervised lesion segmentation and multi-dimensional quantification by adopting a three-dimensional generative reconstruction network, completes image-text feature fine-grained alignment through cross-modal contrast learning of an adversarial enhancement, and fuses multi-dimensional features.The model can complete multiple tasks such as ARDS diagnosis, non-invasive estimation of P / F ratio, severity grading and prognosis prediction in parallel, reduces dependence on artificial labeling, improves cross-center generalization capability and diagnosis precision, and provides a standardized intelligent tool for clinical evaluation of severe lung inflammation.

Compositions and methods for treating chronic obstructive pulmonary disease, interstitial lung disease, asthma, bronchitis, pneumonia, cystic fibrosis, pulmonary edema, sarcoidosis, idiopathic pulmonary fibrosis, pulmonary arterial hypertension, acute respiratory distress syndrome, and respiratory syncytial virus in a patient are presented. Embodiments of the composition include a combination of diethylcarbamazine (DEC) and a prostacyclin analogue, such as Beraprost, Beraprost sodium, Iloprost, Treprostinil, Treprostinil Palmitil, and Cicaprost. Other embodiments include fluvoxamine and / or a phosphodiesterase (PDE) inhibitor. Some embodiments of the composition are in the form of an aerosol, include a propellent, or are in an inhalation delivery device.

The invention discloses application of CD177 in diagnosis and treatment of inflammatory lung injury. The research determines that the neutrophil surface molecule CD177 is obviously and abnormally increased in a patient with acute respiratory distress syndrome (ARDS) and is a reliable immune target for diagnosing lung injury; animal experiments prove that the CD177 has a key therapeutic effect in acute lung injury: the deficiency of the CD177 can obviously inhibit excessive infiltration of neutrophil in lung tissues, and the acute lung injury of mice is relieved.

The invention discloses application of irisin in treatment of acute lung injury / acute respiratory distress syndrome. The research finds that the plasma irisin level is obviously reduced in ARDS patients, and the survival prognosis of the patients with the lower irisin level is poorer. Neutrophil as the most inflammatory cells is a cause for promoting lung tissue injury. Further analysis finds that the level of irisin is in negative correlation with the number of circulating neutrophils, and irisin incubation can significantly reduce in-vitro survival promoting (apoptosis delay) phenotypes of neutrophils in ARDS mouse alveolar lavage fluid. Iris receptor integrin alphaVbeta5 inhibitor treatment can promote neutrophil infiltration and aggravate an ARDS process. The invention provides a novel therapeutic drug and strategy for the treatment of acute lung injury / acute respiratory distress syndrome.

The invention belongs to the technical field of biological medicine, provides novel application of PRMT6, and particularly relates to application of a PRMT6 inhibitor in preparation of a medicine for preventing or treating sepsis-ARDS. The invention discloses the application value of the PRMT6 as the sepsis-ARDS treatment target for the first time. According to the application disclosed by the invention, the expression of PRMT6 is inhibited in a targeted manner, ferroptosis in alveolar epithelial cells (AECs) can be effectively inhibited, and the histopathology related to ARDS is further improved, so that the disease progress is effectively improved, and a new path is opened up for targeted therapy of sepsis-ARDS.

The application provides a use of a teriparatide acetate in preparation of a medicine for preventing and / or treating acute respiratory distress syndrome, and belongs to the technical field of medicines.The application finds that after a mouse with acute respiratory distress syndrome (ARDS) is injected with the teriparatide acetate, neutrophil infiltration can be effectively reduced, and lung hemorrhage, lung capillary hyperemia and lung capillary septum thickening and other lung injury symptoms can be reduced.In addition, the teriparatide acetate can effectively prevent the occurrence of ARDS, can reduce the lung injury degree of the mouse, can reduce the neutrophil infiltration, lung hemorrhage and lung capillary hyperemia and other symptoms, can reduce the level of inflammatory factors in serum, and can reduce lung edema.Therefore, the teriparatide acetate can not only be used for treating acute respiratory syndrome and acute lung injury, but also can prevent the occurrence and development of acute respiratory syndrome, has a remarkable effect, is high in safety, and has a wide application prospect.

The invention belongs to the field of biological medicine, and particularly discloses a culture method of domesticated mesenchymal stem cells (MSCs), which comprises the following steps: separating plasma and platelet lysis buffer from autologous peripheral blood, and obtaining CTL and Treg through magnetic bead sorting; the method comprises the following steps: sequentially co-culturing umbilical cord MSCs for three generations: co-culturing the P1 generation and CTL in a culture medium containing 30% of alpha MEM, 68% of DMEM / F12, 1% of autologous plasma and 1% of platelet lysis buffer, and adding 0.1-1 [mu] M of resveratrol and 10-50 [mu] M of spermidine; co-culturing P2 and Treg in a culture medium containing 50% of alpha MEM, 48% of DMEM / F12, 1% of autologous plasma and 1% of platelet lysis buffer; the P3 generation is cultured and harvested in 90% of alpha MEM, 5% of DMEM / F12 and 5% of PRP. The obtained MSCs surface marker is CD105 < + > / CD90 < + > / CD73 < + > / CD45 <-> / CD34 <-> / HLA-DR <->, the expression quantity of CD24 is low (CD24low), the expression quantity of CD47 is high (CD47high), the expression quantity of PD-L1 is high (PD-L1 high), the IDO activity is larger than or equal to 25 U / mg, the retention rate of the lung after vein transplantation is smaller than or equal to 12%, and the survival period is larger than or equal to 28 days. The cell is suitable for treating ARDS or hepatic fibrosis.

This invention discloses the application of rhubarb-derived exosome-like nanovesicles in the preparation of a drug for treating acute respiratory distress syndrome (ARDS) induced by severe acute pancreatitis, belonging to the field of nanomedicine technology. This invention is the first to propose the application of rhubarb-derived exosome-like nanovesicles in the preparation of a drug for treating ARDS induced by severe acute pancreatitis, providing a new method for treating ARDS and expanding the application of rhubarb-derived exosome-like nanovesicles in the pharmaceutical field. This invention is also the first to propose using rhubarb-derived exosome-like nanovesicles as the active ingredient in a pharmaceutical composition for treating ARDS induced by severe acute pancreatitis.

Disclosed herein are methods for treating acute respiratory distress syndrome, lung injury, respiratory failure, and associated conditions using activators of Tie-2 and inhibitors of HPTPβ. The methods include reducing vascular leak and permeability, reducing edema, reducing inflammation, and increasing oxygen exchange capacity in the lungs.

Disclosed herein are methods of decreasing mucus hypersecretion in the lungs comprising administering an effective amount of a MUC1 inhibitor to a subject in need thereof. In certain embodiments, the MUC1 inhibitor is the peptide GO-201, GO-203, or GO-203-2C. In certain embodiments, the subject is a human patient. In certain embodiments, the subject is diagnosed with rhinosinusitis, chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema, bronchiectasis, asthma, idiopathic pulmonary fibrosis, acute respiratory distress syndrome (ARDS), cystic fibrosis, or a respiratory syncytial virus (RSV) infection.

The invention discloses a kit for detecting susceptibility and severity of children acute respiratory distress syndrome, and relates to the technical field of biomedical detection. The kit comprises a detection reagent combination and a standardized reference system, the detection reagent combination is prepared from specific binding angiogenin 2, a soluble advanced glycosylation end product receptor, pulmonary surfactant protein D, a soluble tumor necrosis factor receptor 1, interleukin 6, interleukin 8, a plasminogen activator inhibitor 1 and a capture and detection antibody of III type procollagen N-terminal peptide. The primer pair and the probe are used for specifically amplifying a single nucleotide polymorphism site rs4073 in a promoter region of the interleukin 8 gene; the standardized reference product system comprises gradient standard products covering the physiological concentration dynamic ranges of the markers on the 0th day, the 3rd day and the 7th day of morbidity; the kit is used for early-stage precise layering and dynamic prognosis evaluation of the acute respiratory distress syndrome of children.

The application discloses application of a group of clinical indexes in preparation of a product for subtyping of ARDS patients complicated with AKI, and constructs a Transformer model for subtyping of ARDS patients complicated with AKI and an ARDS patient complicated with AKI subtyping device based on the Transformer model in combination with the clinical indexes. The ARDS patient complicated with AKI subtyping device can realize accurate and automatic subtyping of ARDS patients complicated with AKI, effectively divides the ARDS patients complicated with AKI into three subtypes with different disease progressions, and then realizes individualized treatment of ARDS patients complicated with AKI with different disease progressions, and the subtyping result has excellent generalization and clinical interpretability.

Methods of improving ARDS by regulating a stellate ganglion is provided herein. Methods of improving a hypercoagulation state are also provided by regulating the sympathetic nervous system.